{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:44:47Z","timestamp":1792449887730,"version":"4.5.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Institue of Health Research","award":["OV5-170710"],"award-info":[{"award-number":["OV5-170710"]}]},{"name":"Research of Manitoba","award":["OV5-170710"],"award-info":[{"award-number":["OV5-170710"]}]},{"DOI":"10.13039\/100008794","name":"Research Manitoba","doi-asserted-by":"publisher","award":["Manitoba Research Chair Award"],"award-info":[{"award-number":["Manitoba Research Chair Award"]}],"id":[{"id":"10.13039\/100008794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008794","name":"Research Manitoba","doi-asserted-by":"publisher","award":["PhD Scholarship from Research Manitoba\/Manitoba Institute of Child HealthResearch Manitoba\/Manitoba Institute of Child Health"],"award-info":[{"award-number":["PhD Scholarship from Research Manitoba\/Manitoba Institute of Child HealthResearch Manitoba\/Manitoba Institute of Child Health"]}],"id":[{"id":"10.13039\/100008794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Until now, antiviral therapeutic agents are still urgently required for treatment or prevention of SARS-coronavirus 2 (SCoV-2) virus infection. In this study, we established a sensitive SCoV-2 Spike glycoprotein (SP), including an SP mutant D614G, pseudotyped HIV-1-based vector system and tested their ability to infect ACE2-expressing cells. Based on this system, we have demonstrated that an aqueous extract from the Natural herb <jats:italic>Prunella vulgaris<\/jats:italic> (NhPV) displayed potent inhibitory effects on SCoV-2 SP (including SP<jats:sub>G614<\/jats:sub> mutant) pseudotyped virus (SCoV-2-SP-PVs) mediated infections. Moreover, we have compared NhPV with another compound, Suramin, for their anti-SARS-CoV-2 activities and the mode of their actions, and found that both NhPV and Suramin are able to directly interrupt SCoV-2\u2013SP binding to its receptor ACE2 and block the viral entry step. Importantly, the inhibitory effects of NhPV and Suramin were confirmed by the wild type SARS-CoV-2 (hCoV-19\/Canada\/ON-VIDO-01\/2020) virus infection in Vero cells. Furthermore, our results also demonstrated that the combination of NhPV\/Suramin with an anti-SARS-CoV-2 neutralizing antibody mediated a more potent blocking effect against SCoV2-SP-PVs. Overall, by using SARS-CoV-2 SP-pseudotyped HIV-1-based entry system, we provide strong evidence that NhPV and Suramin have anti-SARS-CoV-2 activity and may be developed as a novel antiviral approach against SARS-CoV-2 infection.<\/jats:p>","DOI":"10.1371\/journal.pone.0251649","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T18:11:49Z","timestamp":1623262309000},"page":"e0251649","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry"],"prefix":"10.1371","volume":"16","author":[{"given":"Zhujun","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mable","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie Jing","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus Abiola","family":"Olukitibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3200-9638","authenticated-orcid":true,"given":"Mona","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwyn","family":"Kobasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5022-1309","authenticated-orcid":true,"given":"Xiaojian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"pone.0251649.ref001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia","volume":"382","author":"Q Li","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0251649.ref002","doi-asserted-by":"crossref","first-page":"E666","DOI":"10.1503\/cmaj.200711","article-title":"Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States","volume":"192","author":"E Abdollahi","year":"2020","journal-title":"CMAJ"},{"key":"pone.0251649.ref003","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1473-3099(20)30195-X","article-title":"Real estimates of mortality following COVID-19 infection","volume":"20","author":"D Baud","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pone.0251649.ref004","author":"Organization WH","year":"2020","journal-title":"Estimating mortality from COVID-19 Scientific brief"},{"key":"pone.0251649.ref005","first-page":"9089473","volume-title":"Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome","author":"Y-Z Zhang","year":"2020"},{"key":"pone.0251649.ref006","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00415-020-09929-7","article-title":"Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms","volume":"267","author":"Z Zhou","year":"2020","journal-title":"J Neurol"},{"key":"pone.0251649.ref007","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fneur.2020.00518","article-title":"Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review","volume":"11","author":"MU Ahmed","year":"2020","journal-title":"Front Neurol"},{"key":"pone.0251649.ref008","first-page":"948 e941","article-title":"Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19","volume":"26","author":"GU Kim","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"pone.0251649.ref009","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gutjnl-2020-321013","article-title":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection","volume":"69","author":"L Lin","year":"2020","journal-title":"Gut"},{"key":"pone.0251649.ref010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2014.01.010","article-title":"MERS: emergence of a novel human coronavirus","volume":"5","author":"VS Raj","year":"2014","journal-title":"Current opinion in virology"},{"key":"pone.0251649.ref011","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"S Su","year":"2016","journal-title":"Trends in microbiology"},{"key":"pone.0251649.ref012","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","author":"R Lu","year":"2020","journal-title":"Lancet"},{"key":"pone.0251649.ref013","doi-asserted-by":"crossref","first-page":"101212","DOI":"10.1016\/j.isci.2020.101212","article-title":"Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1\/S2 Site","volume":"23","author":"JA Jaimes","year":"2020","journal-title":"iScience"},{"key":"pone.0251649.ref014","article-title":"Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2","author":"B. FW Korber","year":"2020","journal-title":"bioRxiv"},{"key":"pone.0251649.ref015","first-page":"148726","article-title":"The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity","author":"CBJ Lizhou Zhang","year":"2020","journal-title":"bioRxiv 06.12."},{"key":"pone.0251649.ref016","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"B Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0251649.ref017","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"J Grein","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pone.0251649.ref018","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u00ce\u00b1-ketoamide inhibitors","volume":"368","author":"L Zhang","year":"2020","journal-title":"Science"},{"key":"pone.0251649.ref019","article-title":"Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis","author":"D Huang","year":"2020","journal-title":"J Med Virol"},{"key":"pone.0251649.ref020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"M Wang","year":"2020","journal-title":"Cell Res"},{"key":"pone.0251649.ref021","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13020-020-00353-7","article-title":"Current strategies against COVID-19","volume":"15","author":"S Hussain","year":"2020","journal-title":"Chin Med"},{"key":"pone.0251649.ref022","article-title":"Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets","volume":"11","author":"S-J Park","year":"2020","journal-title":"Mbio"},{"key":"pone.0251649.ref023","first-page":"39","article-title":"Experimental study of 472 herbs with antiviral action against the herpes simplex virus","volume":"10","author":"M Zheng","year":"1990","journal-title":"Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine\/Zhongguo Zhong xi yi jie he yan jiu hui (chou), Zhong yi yan jiu yuan, zhu ban"},{"key":"pone.0251649.ref024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0042-6822(92)90294-Y","article-title":"Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris","volume":"187","author":"XJ Yao","year":"1992","journal-title":"Virology"},{"key":"pone.0251649.ref025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.antiviral.2016.01.001","article-title":"Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection","volume":"127","author":"X Zhang","year":"2016","journal-title":"Antiviral Res"},{"key":"pone.0251649.ref026","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0024-3205(02)01939-2","article-title":"Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte","volume":"71","author":"S Liu","year":"2002","journal-title":"Life Sci"},{"key":"pone.0251649.ref027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0166-3542(99)00053-4","article-title":"Isolation and characterization of an anti-HSV polysaccharide from Prunella vulgaris","volume":"44","author":"HX Xu","year":"1999","journal-title":"Antiviral Res"},{"key":"pone.0251649.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0166-3542(87)90034-9","article-title":"Suramin in the treatment of AIDS: mechanism of action","volume":"7","author":"E De Clercq","year":"1987","journal-title":"Antiviral Res"},{"key":"pone.0251649.ref029","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.1987.03400100081025","article-title":"Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group","volume":"258","author":"BD Cheson","year":"1987","journal-title":"JAMA"},{"key":"pone.0251649.ref030","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-199111000-00021","article-title":"The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin","volume":"5","author":"XJ Yao","year":"1991","journal-title":"AIDS"},{"key":"pone.0251649.ref031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2016.07.025","article-title":"Suramin treatment reduces chikungunya pathogenesis in mice","volume":"134","author":"SC Kuo","year":"2016","journal-title":"Antiviral Res"},{"key":"pone.0251649.ref032","article-title":"Suramin inhibits SARS-CoV-2 infection in cell culture by interfering 1 with early steps of the replication cycle","author":"MT Clarisse Salgado Benvindo da Silva","year":"2020","journal-title":"bioRxiv"},{"key":"pone.0251649.ref033","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jviromet.2015.11.019","article-title":"Characterization of the single cycle replication of HIV-1 expressing Gaussia luciferase in human PBMCs, macrophages, and in CD4(+) T cell-grafted nude mouse","volume":"228","author":"Z Ao","year":"2016","journal-title":"J Virol Methods"},{"key":"pone.0251649.ref034","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clim.2011.08.008","article-title":"Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies","volume":"141","author":"X Qiu","year":"2011","journal-title":"Clinical immunology"},{"key":"pone.0251649.ref035","doi-asserted-by":"crossref","first-page":"13456","DOI":"10.1074\/jbc.M610546200","article-title":"Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication","volume":"282","author":"Z Ao","year":"2007","journal-title":"Journal of Biological Chemistry"},{"key":"pone.0251649.ref036","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/AAC.00100-13","article-title":"Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection","volume":"57","author":"L Chen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0251649.ref037","article-title":"Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting","author":"JK Millet","year":"2019","journal-title":"J Vis Exp"},{"key":"pone.0251649.ref038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.virol.2005.06.046","article-title":"Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion","volume":"341","author":"CM Petit","year":"2005","journal-title":"Virology"},{"key":"pone.0251649.ref039","author":"LR Jarek Juraszek","year":"2020","journal-title":"Stabilizing the Closed SARS-CoV-2 Spike Trimer bioRxiv"},{"key":"pone.0251649.ref040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12038-017-9676-7","article-title":"Cytoplasmic tail of coronavirus spike protein has intracellular targeting signals","volume":"42","author":"J Sadasivan","year":"2017","journal-title":"J Biosci"},{"key":"pone.0251649.ref041","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/JVI.02146-06","article-title":"The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein","volume":"81","author":"CE McBride","year":"2007","journal-title":"J Virol"},{"key":"pone.0251649.ref042","author":"C-LH Jie Hu","year":"2020","journal-title":"The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity 1 and decreases neutralization sensitivity to individual convalescent sera bioRxiv"},{"key":"pone.0251649.ref043","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses","volume":"41","author":"S-B Jiang","year":"2020","journal-title":"Trends in immunology"},{"key":"pone.0251649.ref044","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"R Wolfel","year":"2020","journal-title":"Nature"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T18:12:27Z","timestamp":1623262347000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251649"}},"subtitle":[],"editor":[{"given":"Shan","family":"Cen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0251649","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]}}}